Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Cristina Rosa Ferrone, M.D.

Co-Author

This page shows the publications co-authored by Cristina Ferrone and Keith Lillemoe.
Connection Strength

9.727
  1. Assessment of the Long-Term Impact of Pancreatoduodenectomy on Health-Related Quality of Life Using the EORTC QLQ-PAN26 Module. Ann Surg Oncol. 2021 Aug; 28(8):4216-4224.
    View in: PubMed
    Score: 0.238
  2. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. J Natl Cancer Inst. 2021 02 01; 113(2):182-191.
    View in: PubMed
    Score: 0.236
  3. Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy. J Gastrointest Surg. 2021 Jan 26.
    View in: PubMed
    Score: 0.236
  4. Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoadjuvant FOLFIRINOX and Chemoradiation. Ann Surg Oncol. 2021 Aug; 28(8):4592-4601.
    View in: PubMed
    Score: 0.235
  5. Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma. Ann Surg. 2020 Oct 19.
    View in: PubMed
    Score: 0.231
  6. A multi-institutional study of patient-derived gender-based discrimination experienced by resident physicians. Am J Surg. 2021 02; 221(2):309-314.
    View in: PubMed
    Score: 0.231
  7. Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer. Ann Surg. 2020 08; 272(2):357-365.
    View in: PubMed
    Score: 0.228
  8. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Ann Surg. 2019 04; 269(4):733-740.
    View in: PubMed
    Score: 0.208
  9. Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs). Clin Cancer Res. 2019 04 15; 25(8):2644-2655.
    View in: PubMed
    Score: 0.205
  10. Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer. Ann Surg. 2019 Jan 18.
    View in: PubMed
    Score: 0.205
  11. Are Staging Computed Tomography (CT) Scans of the Chest Necessary in Pancreatic Adenocarcinoma? Ann Surg Oncol. 2018 Dec; 25(13):3936-3942.
    View in: PubMed
    Score: 0.201
  12. Staging Laparoscopy Not Only Saves Patients an Incision, But May Also Help Them Live Longer. Ann Surg Oncol. 2018 Apr; 25(4):1009-1016.
    View in: PubMed
    Score: 0.191
  13. Hospital readmission after distal pancreatectomy is predicted by specific intra- and post-operative factors. Am J Surg. 2018 09; 216(3):511-517.
    View in: PubMed
    Score: 0.190
  14. Ductal Carcinoma Arising in a Largely Unchanged Presumed Branch-duct IPMN After 10 Years of Surveillance. Ann Surg. 2017 Dec; 266(6):e38-e40.
    View in: PubMed
    Score: 0.189
  15. Health-related Quality of Life and Functional Outcomes in 5-year Survivors After Pancreaticoduodenectomy. Ann Surg. 2017 10; 266(4):685-692.
    View in: PubMed
    Score: 0.187
  16. Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases. J Gastrointest Surg. 2017 Nov; 21(11):1831-1840.
    View in: PubMed
    Score: 0.186
  17. Reappraisal of Staging Laparoscopy for Patients with Pancreatic Adenocarcinoma: A Contemporary Analysis of 1001 Patients. Ann Surg Oncol. 2017 Oct; 24(11):3203-3211.
    View in: PubMed
    Score: 0.184
  18. Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors. Ann Surg Oncol. 2016 12; 23(Suppl 5):609-617.
    View in: PubMed
    Score: 0.168
  19. Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma. J Gastrointest Surg. 2016 05; 20(5):953-9.
    View in: PubMed
    Score: 0.168
  20. Operative Versus Nonoperative Management of Nonfunctioning Pancreatic Neuroendocrine Tumors. J Gastrointest Surg. 2016 Feb; 20(2):277-83.
    View in: PubMed
    Score: 0.165
  21. Erratum to: The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S1609.
    View in: PubMed
    Score: 0.165
  22. Erratum to: The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S1604.
    View in: PubMed
    Score: 0.165
  23. Health Insurance Expansion and Treatment of Pancreatic Cancer: Does Increased Access Lead to Improved Care? J Am Coll Surg. 2015 Dec; 221(6):1015-22.
    View in: PubMed
    Score: 0.163
  24. PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. Clin Cancer Res. 2016 Jan 15; 22(2):470-8.
    View in: PubMed
    Score: 0.162
  25. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015 Jan; 261(1):12-7.
    View in: PubMed
    Score: 0.155
  26. The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology. Ann Surg Oncol. 2016 Jan; 23(1):290-6.
    View in: PubMed
    Score: 0.154
  27. Lymphoepithelial cysts and cystic lymphangiomas: Under-recognized benign cystic lesions of the pancreas. World J Gastrointest Surg. 2014 Jul 27; 6(7):136-41.
    View in: PubMed
    Score: 0.150
  28. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection? Ann Surg. 2013 Apr; 257(4):731-6.
    View in: PubMed
    Score: 0.137
  29. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery. 2012 Sep; 152(3 Suppl 1):S43-9.
    View in: PubMed
    Score: 0.130
  30. The Impact of Neoadjuvant Treatment on Survival in Patients Undergoing Pancreatoduodenectomy With Concomitant Portomesenteric Venous Resection: An International Multicenter Analysis. Ann Surg. 2021 11 01; 274(5):721-728.
    View in: PubMed
    Score: 0.062
  31. Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapy. Eur Radiol. 2021 Oct 19.
    View in: PubMed
    Score: 0.062
  32. "Evolving Trends in Pancreatic Cystic Tumors: A 3-Decade Single-Center Experience with 1290 Resections". Ann Surg. 2021 Aug 04.
    View in: PubMed
    Score: 0.061
  33. Simulated Volume-Based Regionalization of Complex Procedures: Impact on Spatial Access to Care. Ann Surg. 2021 08 01; 274(2):312-318.
    View in: PubMed
    Score: 0.061
  34. Revision of Pancreatic Neck Margins Based on Intraoperative Frozen Section Analysis Is Associated With Improved Survival in Patients Undergoing Pancreatectomy for Ductal Adenocarcinoma. Ann Surg. 2021 08 01; 274(2):e134-e142.
    View in: PubMed
    Score: 0.061
  35. Influence of Klebsiella pneumoniae and quinolone treatment on prognosis in patients with pancreatic cancer. Br J Surg. 2021 06 22; 108(6):709-716.
    View in: PubMed
    Score: 0.061
  36. Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes. Pancreatology. 2021 May 15.
    View in: PubMed
    Score: 0.060
  37. Analysis of in court malpractice litigation following pancreatic surgery. Pancreatology. 2021 Jun; 21(4):819-823.
    View in: PubMed
    Score: 0.059
  38. Patient and Caregiver Considerations and Priorities When Selecting Hospitals for Complex Cancer Care. Ann Surg Oncol. 2021 Aug; 28(8):4183-4192.
    View in: PubMed
    Score: 0.059
  39. Reassessment of the Optimal Number of Examined Lymph Nodes in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. Ann Surg. 2020 Nov 09.
    View in: PubMed
    Score: 0.058
  40. Size of the Largest Colorectal Liver Metastasis Is an Independent Prognostic Factor in the Neoadjuvant Setting. J Surg Res. 2021 03; 259:253-260.
    View in: PubMed
    Score: 0.058
  41. Defining Benchmark Outcomes for Pancreatoduodenectomy With Portomesenteric Venous Resection. Ann Surg. 2020 11; 272(5):731-737.
    View in: PubMed
    Score: 0.058
  42. Implications of Perineural Invasion on Disease Recurrence and Survival After Pancreatectomy for Pancreatic Head Ductal Adenocarcinoma. Ann Surg. 2020 Oct 19.
    View in: PubMed
    Score: 0.058
  43. Influence of Klebsiella pneumoniae and quinolone treatment on prognosis in patients with pancreatic cancer. Br J Surg. 2020 Sep 30.
    View in: PubMed
    Score: 0.058
  44. Neoplastic-Stromal Cell Cross-talk Regulates Matrisome Expression in Pancreatic Cancer. Mol Cancer Res. 2020 12; 18(12):1889-1902.
    View in: PubMed
    Score: 0.057
  45. Preoperative cholangitis is an independent risk factor for mortality in patients after pancreatoduodenectomy for pancreatic cancer. Am J Surg. 2021 01; 221(1):134-140.
    View in: PubMed
    Score: 0.057
  46. Risk of malignancy in small pancreatic cysts decreases over time. Pancreatology. 2020 Sep; 20(6):1213-1217.
    View in: PubMed
    Score: 0.057
  47. Evaluation of Pathologic Response on Overall Survival After Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Pancreas. 2020 08; 49(7):897-903.
    View in: PubMed
    Score: 0.057
  48. A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: The PANAMA-score. Ann Surg. 2020 Jul 07.
    View in: PubMed
    Score: 0.057
  49. Microscopic size measurements in post-neoadjuvant therapy resections of pancreatic ductal adenocarcinoma (PDAC) predict patient outcomes. Histopathology. 2020 Jul; 77(1):144-155.
    View in: PubMed
    Score: 0.057
  50. Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation. Histopathology. 2020 Jul; 77(1):35-45.
    View in: PubMed
    Score: 0.056
  51. Reappraising the Concept of Conditional Survival After Pancreatectomy for Ductal Adenocarcinoma: A Bi-institutional Analysis. Ann Surg. 2020 06; 271(6):1148-1155.
    View in: PubMed
    Score: 0.056
  52. Diagnosis of Depression is Associated with Readmission Following Elective Pancreatectomy. Ann Surg Oncol. 2020 Oct; 27(11):4544-4550.
    View in: PubMed
    Score: 0.056
  53. Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2020 Oct; 27(10):3898-3912.
    View in: PubMed
    Score: 0.056
  54. An elevated CA 19-9 is associated with invasive cancer and worse survival in IPMN. Pancreatology. 2020 Jun; 20(4):729-735.
    View in: PubMed
    Score: 0.056
  55. Variation in long-term oncologic outcomes by type of cancer center accreditation: An analysis of a SEER-Medicare population with pancreatic cancer. Am J Surg. 2020 07; 220(1):29-34.
    View in: PubMed
    Score: 0.056
  56. Impact of adjuvant therapy in patients with invasive intraductal papillary mucinous neoplasms of the pancreas. Pancreatology. 2020 Jun; 20(4):722-728.
    View in: PubMed
    Score: 0.055
  57. Clinical staging in pancreatic adenocarcinoma underestimates extent of disease. Pancreatology. 2020 Jun; 20(4):691-697.
    View in: PubMed
    Score: 0.055
  58. Intraductal Papillary Mucinous Neoplasms: Have IAP Consensus Guidelines Changed our Approach?: Results from a Multi-institutional Study. Ann Surg. 2019 Dec 05.
    View in: PubMed
    Score: 0.054
  59. Number of Examined Lymph Nodes and Nodal Status Assessment in Distal Pancreatectomy for Body/Tail Ductal Adenocarcinoma. Ann Surg. 2019 12; 270(6):1138-1146.
    View in: PubMed
    Score: 0.054
  60. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes. Ann Surg Oncol. 2020 May; 27(5):1400-1406.
    View in: PubMed
    Score: 0.054
  61. Main Pancreatic Duct to Parenchymal Thickness Ratio at Preoperative Imaging is Associated with Overall Survival in Upfront Resected Pancreatic Cancer. Ann Surg Oncol. 2020 May; 27(5):1606-1612.
    View in: PubMed
    Score: 0.054
  62. Does preoperative pharmacologic prophylaxis reduce the rate of venous thromboembolism in pancreatectomy patients? HPB (Oxford). 2020 07; 22(7):1020-1024.
    View in: PubMed
    Score: 0.054
  63. Diabetes mellitus is associated with unfavorable pathologic features, increased postoperative mortality, and worse long-term survival in resected pancreatic cancer. Pancreatology. 2020 Jan; 20(1):125-131.
    View in: PubMed
    Score: 0.054
  64. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy. JAMA Surg. 2019 10 01; 154(10):943-951.
    View in: PubMed
    Score: 0.054
  65. Benchmarks in Pancreatic Surgery: A Novel Tool for Unbiased Outcome Comparisons. Ann Surg. 2019 08; 270(2):211-218.
    View in: PubMed
    Score: 0.053
  66. Facility Type is Associated with Margin Status and Overall Survival of Patients with Resected Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2019 Nov; 26(12):4091-4099.
    View in: PubMed
    Score: 0.053
  67. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Jul 01; 5(7):1020-1027.
    View in: PubMed
    Score: 0.053
  68. Cross Validation of the Monoclonal Antibody Das-1 in Identification of High-Risk Mucinous Pancreatic Cystic Lesions. Gastroenterology. 2019 09; 157(3):720-730.e2.
    View in: PubMed
    Score: 0.053
  69. Predictors of adjuvant treatment and survival in patients with intrahepatic cholangiocarcinoma who undergo resection. Am J Surg. 2019 11; 218(5):959-966.
    View in: PubMed
    Score: 0.052
  70. Intraoperative Fluid Administration and Surgical Outcomes Following Pancreaticoduodenectomy: External Validation at a Tertiary Referral Center. World J Surg. 2019 Mar; 43(3):929-936.
    View in: PubMed
    Score: 0.052
  71. Quasimesenchymal phenotype predicts systemic metastasis in pancreatic ductal adenocarcinoma. Mod Pathol. 2019 06; 32(6):844-854.
    View in: PubMed
    Score: 0.051
  72. Surgical resection versus ablation for early-stage hepatocellular carcinoma: A retrospective cohort analysis. Am J Surg. 2019 07; 218(1):157-163.
    View in: PubMed
    Score: 0.051
  73. Lower phosphate levels following pancreatectomy is associated with postoperative pancreatic fistula formation. HPB (Oxford). 2019 07; 21(7):834-840.
    View in: PubMed
    Score: 0.051
  74. Intraoperative Dexamethasone Decreases Infectious Complications After Pancreaticoduodenectomy and is Associated with Long-Term Survival in Pancreatic Cancer. Ann Surg Oncol. 2018 Dec; 25(13):4020-4026.
    View in: PubMed
    Score: 0.050
  75. Major Complications Independently Increase Long-Term Mortality After Pancreatoduodenectomy for Cancer. J Gastrointest Surg. 2019 10; 23(10):1984-1990.
    View in: PubMed
    Score: 0.050
  76. Association Between Changes in Body Composition and Neoadjuvant Treatment for Pancreatic Cancer. JAMA Surg. 2018 09 01; 153(9):809-815.
    View in: PubMed
    Score: 0.050
  77. Multi-institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-risk Intraductal Papillary Mucinous Neoplasms of the Pancreas. Ann Surg. 2018 08; 268(2):340-347.
    View in: PubMed
    Score: 0.050
  78. Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer. Am J Clin Oncol. 2018 07; 41(7):656-661.
    View in: PubMed
    Score: 0.049
  79. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2018 07 01; 4(7):963-969.
    View in: PubMed
    Score: 0.049
  80. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma. Am J Clin Oncol. 2018 06; 41(6):607-612.
    View in: PubMed
    Score: 0.049
  81. Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas: A Report from The Pancreatic Surgery Consortium. Ann Surg. 2018 01; 267(1):157-163.
    View in: PubMed
    Score: 0.048
  82. Intraductal Papillary Mucinous Neoplasm of the Pancreas in Young Patients: Tumor Biology, Clinical Features, and Survival Outcomes. J Gastrointest Surg. 2018 02; 22(2):226-234.
    View in: PubMed
    Score: 0.047
  83. Diabetes mellitus in intraductal papillary mucinous neoplasm of the pancreas is associated with high-grade dysplasia and invasive carcinoma. Pancreatology. 2017 Nov - Dec; 17(6):920-926.
    View in: PubMed
    Score: 0.047
  84. Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival. PLoS One. 2017; 12(8):e0182855.
    View in: PubMed
    Score: 0.046
  85. A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram. Cancer Lett. 2017 11 28; 409:9-19.
    View in: PubMed
    Score: 0.046
  86. Long-term Risk of Pancreatic Malignancy in Patients With Branch Duct Intraductal Papillary Mucinous Neoplasm in a Referral Center. Gastroenterology. 2017 11; 153(5):1284-1294.e1.
    View in: PubMed
    Score: 0.046
  87. Primary lymph node gastrinoma: A single institution experience. Surgery. 2017 11; 162(5):1088-1094.
    View in: PubMed
    Score: 0.046
  88. Does Size Matter in Pancreatic Cancer?: Reappraisal of Tumour Dimension as a Predictor of Outcome Beyond the TNM. Ann Surg. 2017 07; 266(1):142-148.
    View in: PubMed
    Score: 0.046
  89. Microscopic lymphovascular invasion is an independent predictor of survival in resected pancreatic ductal adenocarcinoma. J Surg Oncol. 2017 Nov; 116(6):658-664.
    View in: PubMed
    Score: 0.046
  90. Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2017 Oct 01; 23(19):5959-5969.
    View in: PubMed
    Score: 0.046
  91. Potential impact of a volume pledge on spatial access: A population-level analysis of patients undergoing pancreatectomy. Surgery. 2017 08; 162(2):203-210.
    View in: PubMed
    Score: 0.046
  92. Predictors of Early Mortality After Surgical Resection of Pancreatic Adenocarcinoma in the Era of Neoadjuvant Treatment. Pancreas. 2017 02; 46(2):183-189.
    View in: PubMed
    Score: 0.045
  93. Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma. Ann Surg. 2017 01; 265(1):185-191.
    View in: PubMed
    Score: 0.044
  94. Solid pseudopapillary tumors of the pancreas: Specific pathological features predict the likelihood of postoperative recurrence. J Surg Oncol. 2016 Oct; 114(5):597-601.
    View in: PubMed
    Score: 0.043
  95. Discordance Between Perioperative Antibiotic Prophylaxis and Wound Infection Cultures in Patients Undergoing Pancreaticoduodenectomy. JAMA Surg. 2016 05 01; 151(5):432-9.
    View in: PubMed
    Score: 0.042
  96. Intraductal Papillary Mucinous Neoplasm of the Pancreas: Current State of the Art and Ongoing Controversies. Ann Surg. 2016 May; 263(5):908-17.
    View in: PubMed
    Score: 0.042
  97. Preoperative biliary drainage does not increase major complications in pancreaticoduodenectomy: a large single center experience from the Massachusetts General Hospital. J Hepatobiliary Pancreat Sci. 2016 Mar; 23(3):181-7.
    View in: PubMed
    Score: 0.042
  98. Early National Experience with Laparoscopic Pancreaticoduodenectomy for Ductal Adenocarcinoma: Is This Really a Short Learning Curve? J Am Coll Surg. 2016 Feb; 222(2):209.
    View in: PubMed
    Score: 0.042
  99. Patterns of Recurrence After Resection of IPMN: Who, When, and How? Ann Surg. 2015 Dec; 262(6):1108-14.
    View in: PubMed
    Score: 0.041
  100. Intraductal papillary mucinous neoplasms of the pancreas with concurrent pancreatic and periampullary neoplasms. Eur J Surg Oncol. 2016 Feb; 42(2):197-204.
    View in: PubMed
    Score: 0.041
  101. Early Drain Removal--The Middle Ground Between the Drain Versus No Drain Debate in Patients Undergoing Pancreaticoduodenectomy: A Prospective Validation Study. Ann Surg. 2015 Aug; 262(2):378-83.
    View in: PubMed
    Score: 0.040
  102. Acute pancreatitis in intraductal papillary mucinous neoplasms: A common predictor of malignant intestinal subtype. Surgery. 2015 Nov; 158(5):1219-25.
    View in: PubMed
    Score: 0.040
  103. Effects of Comorbidities on Outcomes of Patients With Intraductal Papillary Mucinous Neoplasms. Clin Gastroenterol Hepatol. 2015 Oct; 13(10):1816-23.
    View in: PubMed
    Score: 0.040
  104. IPMN involving the main pancreatic duct: biology, epidemiology, and long-term outcomes following resection. Ann Surg. 2015 May; 261(5):976-83.
    View in: PubMed
    Score: 0.040
  105. The Charlson age comorbidity index predicts early mortality after surgery for pancreatic cancer. Surgery. 2015 May; 157(5):881-7.
    View in: PubMed
    Score: 0.039
  106. Oncocytic-type intraductal papillary mucinous neoplasms: a unique malignant pancreatic tumor with good long-term prognosis. J Am Coll Surg. 2015 May; 220(5):839-44.
    View in: PubMed
    Score: 0.039
  107. High performing whipple patients: factors associated with short length of stay after open pancreaticoduodenectomy. J Gastrointest Surg. 2014 Oct; 18(10):1760-9.
    View in: PubMed
    Score: 0.038
  108. Not all mixed-type intraductal papillary mucinous neoplasms behave like main-duct lesions: implications of minimal involvement of the main pancreatic duct. Surgery. 2014 Sep; 156(3):611-21.
    View in: PubMed
    Score: 0.038
  109. Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer. Radiother Oncol. 2014 Jan; 110(1):160-4.
    View in: PubMed
    Score: 0.036
  110. Understanding hospital readmissions after pancreaticoduodenectomy: can we prevent them?: a 10-year contemporary experience with 1,173 patients at the Massachusetts General Hospital. J Gastrointest Surg. 2014 Jan; 18(1):137-44; discussion 144-5.
    View in: PubMed
    Score: 0.035
  111. Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010. Cancer. 2013 Dec 01; 119(23):4196-204.
    View in: PubMed
    Score: 0.035
  112. Branch duct intraductal papillary mucinous neoplasms: does cyst size change the tip of the scale? A critical analysis of the revised international consensus guidelines in a large single-institutional series. Ann Surg. 2013 Sep; 258(3):466-75.
    View in: PubMed
    Score: 0.035
  113. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist. 2013; 18(5):543-8.
    View in: PubMed
    Score: 0.034
  114. N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma. J Gastrointest Surg. 2013 Feb; 17(2):257-66.
    View in: PubMed
    Score: 0.034
  115. Evolution of the Whipple procedure at the Massachusetts General Hospital. Surgery. 2012 Sep; 152(3 Suppl 1):S56-63.
    View in: PubMed
    Score: 0.033
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.